Midcap

STRATA Skin Sciences to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, October 6, 2022
Psoriasis, Insurance, Strata Skin Sciences, DTC, Dermatology, NASDAQ, Patient, Vitiligo, Marketing, STRATA, Atopic dermatitis, Midcap, Awareness, GLOBE, Dermatitis, UVB, Acne, FDA, Laser, Medical imaging

For more information, please visit the events webpage, here .

Key Points: 
  • For more information, please visit the events webpage, here .
  • STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions.
  • Its products include the XTRAC, XTRAC Momentum 1.0 and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.
  • In addition, STRATA's TheraClearX, utilizes FDA-Cleared technology to address the estimated $5.5 billion market opportunity for acne treatment with a non-invasive, highly effective, in-office procedure.

MidCap Financial Investment Corporation Schedules Earnings Release and Conference Call for Quarter Ended September 30, 2022

Retrieved on: 
Thursday, October 6, 2022
Conference, NASDAQ, Income, Internal Revenue Code, Midcap, Investment, Private Securities Litigation Reform Act, Investment Company Act of 1940, Company, GLOBE, Forward-looking statement, Shareholder, Bank, Calendar

NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- MidCap Financial Investment Corporation (NASDAQ: MFIC) (the Company) announced today that it will report results for the quarter ended September 30, 2022, after market close on Thursday, November 3, 2022.

Key Points: 
  • NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- MidCap Financial Investment Corporation (NASDAQ: MFIC) (the Company) announced today that it will report results for the quarter ended September 30, 2022, after market close on Thursday, November 3, 2022.
  • The Company will also host a conference call on Thursday, November 3, 2022 at 5:00 p.m. Eastern Time.
  • Participants should reference either MidCap Financial Investment Corporation Earnings or Conference ID: MFIC1103 when prompted.
  • MidCap Financial Investment Corporation (NASDAQ: MFIC) is a closed-end, externally managed, non-diversified management investment company that has elected to be treated as a business development company (BDC) under the Investment Company Act of 1940 (the 1940 Act).

GeoVax to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, October 6, 2022
CA, Head, Vaccine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Malaria, Nasdaq, Cancer, Infection, Food, Company, Immunodeficiency, CEO, Patent, Chief executive officer, GLOBE, FDA, COVID-19, Zika virus, GeoVax, Midcap, Online shopping

In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine.

Key Points: 
  • In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine.
  • The Company is also conducting a Phase 1/2 clinical trial of Gedeptin for treatment of head and neck cancer.
  • The Companys portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at 115 granted or pending patent applications spread over 24 patent families.
  • For additional information about GeoVax, visit our website: www.geovax.com .

Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023

Retrieved on: 
Thursday, October 6, 2022
Customer service, Rheumatoid arthritis, Growth, TSX, Patient, Midcap, Partnership, Health Canada, Marketing, Blood, Treosulfan, World Health Organization, Allergy, Methotrexate, Hematopoietic stem cell transplantation, GLOBE, Hematology, FDA, Glioma, Pharmaceutical industry, Collaboration

TORONTO and CHICAGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX:MDP) (OTCQX:MEDXF) is pleased to announce preliminary estimates of the companys revenue results for the fiscal quarter ended September30, 2022 (the companys fiscal Q2 2023).

Key Points: 
  • TORONTO and CHICAGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX:MDP) (OTCQX:MEDXF) is pleased to announce preliminary estimates of the companys revenue results for the fiscal quarter ended September30, 2022 (the companys fiscal Q2 2023).
  • Medexus expects to deliver total revenue between $27.0million and $27.5million in fiscal Q2 2023.
  • This will represent the strongest fiscal quarter in Medexuss history, and an increase of at least 51% compared to $17.9million in fiscal Q2 2022 and an increase of at least 17% compared to $23.0million in fiscal Q1 2023.
  • We began shipping Medexus-labeled product to customers across the country in August, meaning that September2022 will be the first full month, and fiscal Q3 2023 the first full fiscal quarter, in which Medexus recognizes 100% of Gleolan net sales.

F.N.B. Corporation Receives Final Regulatory Approvals for UB Bancorp Merger

Retrieved on: 
Wednesday, October 5, 2022
F.N.B. Corporation, Insurance, Time, High Point, New, Investor relations, Piedmont Triad, SEC, Structure of the Federal Reserve System, Government, Growth, Standard, Comptroller, GICS, NYSE, Annual report, OCC, Union Bank, District, Global, S&P Global Ratings, Midcap, Condition subsequent, Multimedia, FNB, Company, Industry, Bloomberg L.P. v. Board of Governors of the Federal Reserve System, Board, Small business, OTCQX, Winston-Salem, North Carolina, Federal Reserve, Federal Reserve Board of Governors, Forward-looking statement, Solution, Bank, Security (finance), Risk management

Corporation (NYSE: FNB) announced it has received all regulatory clearances for its proposed merger with UB Bancorp (OTCQX: UBNC).

Key Points: 
  • Corporation (NYSE: FNB) announced it has received all regulatory clearances for its proposed merger with UB Bancorp (OTCQX: UBNC).
  • UB Bancorp stockholders approved the proposed merger at a special meeting on September 21, 2022.
  • As announced on June 1, 2022, UB Bancorp stockholders will be entitled to receive 1.61 shares of FNB common stock for each share of UB Bancorp common stock they own.
  • The exchange ratio is fixed, and the transaction is expected to qualify as a tax-free exchange for UB Bancorp stockholders.

Carbon6 Raises $66M, Acquires 16 Companies to Simplify Success for Ecommerce Entrepreneurs

Retrieved on: 
Tuesday, October 4, 2022
Online Retail, Entrepreneur, Technology, Professional Services, Electronic Commerce, Advertising, Communications, Retail, Data Analytics, Software, Consumer, Solution, Advertising, Freedom, Ecosystem, Software, CEO, Multimedia, Education, Connective tissue, Apollo, Midcap, Online shopping, Amazon

To simplify the online selling process, Carbon6 has acquired 16 software companies in 16 months (between May 2021 and September 2022).

Key Points: 
  • To simplify the online selling process, Carbon6 has acquired 16 software companies in 16 months (between May 2021 and September 2022).
  • Our vision is to become the ecosystem for marketplace entrepreneurs, says Justin Cobb, CEO of Carbon6.
  • With a global network of founders, employees, advisors, and acquired companies, Carbon6 is well positioned to serve the seller wherever they sell.
  • Carbon6 simplifies the success of marketplace entrepreneurs with a connected ecosystem of tools and expertise.

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

Retrieved on: 
Tuesday, October 4, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, EXEL, AXL, S&P, Genentech, SEC, Clinical trial, MET, Nasdaq, Genetics, Drug discovery, Compliance, Medical Affairs Bureau, Twitter, ICIS, COVID-19, Clinical Genitourinary Cancer, Bristol Myers Squibb, Ipilimumab, VEGF, Daiichi Sankyo, T helper cell, TKI, MER, U.S. Securities and Exchange Commission, BMY, Pathology, Safety, NYSE, Midcap, Security (finance), Metastasis, Nivolumab, Relatlimab, Patient, Esaxerenone, Cancer, Forward-looking statement, Standard, Pharmaceutical industry, Kerosene, Facebook, Exelixis, Limited

The novel triplet combination of XL092 and the fixed-dose combination of nivolumab and relatlimab has the potential to be used in multiple expansion cohorts.

Key Points: 
  • The novel triplet combination of XL092 and the fixed-dose combination of nivolumab and relatlimab has the potential to be used in multiple expansion cohorts.
  • XL092 is Exelixis next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancers growth and spread.
  • Bristol Myers Squibbs relatlimab is a lymphocyte activation gene-3 (LAG-3)-blocking antibody.
  • The dose-escalation stage will determine the recommended dose in patients with advanced solid tumors for each of the combination therapy regimens, including XL092 and nivolumab, XL092, nivolumab and ipilimumab, and XL092 and the fixed-dose combination of nivolumab and relatlimab.

F.N.B. Corporation Schedules Third Quarter 2022 Earnings Report and Conference Call

Retrieved on: 
Friday, September 30, 2022
High Point, Piedmont Triad, Global, NYSE, Corporation, F.N.B. Corporation, Company, Midcap, Access, Government, FNB, District, S&P Global Ratings, Solution, GICS, Winston-Salem, North Carolina, Insurance, New, Conference, Small business, Multimedia, Webcast, PIN, Standard, Security (finance), Financial services

Corporation (NYSE: FNB) announced today that it plans to issue financial results for the third quarter of 2022 after the market close on Tuesday, October 18, 2022.

Key Points: 
  • Corporation (NYSE: FNB) announced today that it plans to issue financial results for the third quarter of 2022 after the market close on Tuesday, October 18, 2022.
  • Callers who pre-register will be provided a conference passcode and unique PIN to bypass the live operator and gain immediate access to the call.
  • Dial-in Access: The conference call may be accessed by dialing 844-802-2440 (for domestic callers) or 412-317-5133 (for international callers).
  • A replay of the call will be available shortly after the completion of the call until midnight ET on Wednesday, October 26, 2022.

Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount

Retrieved on: 
Thursday, September 29, 2022
Treosulfan, TSX, Allergy, FDA, Blood, World Health Organization, Customer service, Rheumatoid arthritis, Midcap, Growth, Hematology, Partnership, Patient, Toronto Stock Exchange, Hematopoietic stem cell transplantation, Health Canada, Methotrexate, GLOBE, Glioma, Pharmaceutical industry, Collaboration

TORONTO and CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company’s revolving credit facility with a syndicate of lenders agented by MidCap Funding IV Trust (MidCap). Among other things, the amendment provides for a US$5.0 million increase in MidCap’s revolving loan commitment amount on substantially the same terms provided under the existing facility. Following the amendment, Medexus will have total borrowing capacity under the revolving credit facility of US$25.0 million subject to the borrowing base.

Key Points: 
  • Among other things, the amendment provides for a US$5.0million increase in MidCaps revolving loan commitment amount on substantially the same terms provided under the existing facility.
  • Following the amendment, Medexus will have total borrowing capacity under the revolving credit facility of US$25.0million subject to the borrowing base.
  • We are pleased to extend our strong partnership with MidCap and bolster our liquidity position as we head into this upcoming quarter, commented Marcel Konrad, Chief Financial Officer of Medexus.
  • Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products.

F.N.B. Corporation Commits $1 Million to The Pittsburgh Promise

Retrieved on: 
Thursday, September 29, 2022
High Point, Pittsburgh Public Schools, Piedmont Triad, Workforce, Global, Employment, First National Bank, Human, NYSE, F.N.B. Corporation, Company, Midcap, Mentorship, Partnership, Government, FNB, District, Student, Quality of life, S&P Global Ratings, Goal, Solution, GICS, Winston-Salem, North Carolina, Insurance, New, Small business, Multimedia, Standard, Management, Renewable energy, Promise

Corporation (NYSE: FNB) announced it has increased its total commitment to The Pittsburgh Promise to $1 million.

Key Points: 
  • Corporation (NYSE: FNB) announced it has increased its total commitment to The Pittsburgh Promise to $1 million.
  • Corporation Scholars of The Pittsburgh Promise."
  • Along with officials from The Pittsburgh Promise and Pittsburgh Public Schools, FNB presented the gift at The Pittsburgh Promise's Preferred College Partners Opportunity Fair, where hundreds of students met with representatives from trade, 2-year and 4-year post-secondary schools.
  • Pittsburgh Promise Executive Director Saleem Ghubril commented, "We are so grateful to have FNB as our newest $1 million partner.